Everolimus for cognition/autism in children with tuberous sclerosis complex: Definitive outcomes deferred

Neurology. 2019 Jul 9;93(2):51-52. doi: 10.1212/WNL.0000000000007744. Epub 2019 Jun 19.

Authors

Kevin C Ess¹, David Neal Franz¹

Affiliation

¹ From the Departments of Pediatrics and Neurology (K.C.E.), Vanderbilt University Medical Center, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; and Departments of Pediatrics and Neurology (D.N.F.), University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, OH.

PMID: 31217258
DOI: 10.1212/WNL.0000000000007744

No abstract available

Publication types

Editorial
Comment

MeSH terms

Autistic Disorder*
Child
Cognition
Everolimus
Humans
Immunosuppressive Agents
Tuberous Sclerosis*

Substances

Immunosuppressive Agents
Everolimus